Abstract Introduction/Background Inhibition of tumor angiogenesis by the interruption of
VEGF pathway signaling is of therapeutic value in several solid tumors. Preclinical evidence …

Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …

Purpose The optimal management of stage I follicular lymphoma, according to consensus
guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted
therapies are being investigated as potentially more efficacious and tolerable alternatives for …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in
North America. Because of the heterogeneity of the disease, treatment options vary from …

Background The purpose of this study was to identify prognostic parameters for patients with
follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of …

Follicular lymphoma (FL) is the most common indolent non-hodgkin lymphoma. Most
patients with FL are diagnosed with advanced disease and are considered incurable. The …

INTRODUCTION: For follicular lymphoma (FL) patients (Pts) in need of therapy, frontline
treatment with bendamustine-rituximab (BR) has become a standard treatment option. The …